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High throughputThe translation machinery is the engine of life. Extracting the cytoplasmic milieu from a cell affords
a lysate capable of producing proteins in concentrations reaching to tens of micromolar. Such
lysates, derivable from a variety of cells, allow the facile addition and subtraction of components
that are directly or indirectly related to the translation machinery and/or the over-expressed pro-
tein. The ﬂexible nature of such cell-free expression systems, when coupled with high throughput
monitoring, can be especially suitable for protein engineering studies, allowing one to bypass multi-
ple steps typically required using conventional in vivo protein expression.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ability to produce a functional protein in the test tube,
rather than in cells, is the essence of cell-free protein synthesis
(CFPS) [1,2]. The preparation of a CFPS kit requires the separa-
tion of the cytoplasmic milieu from the cell wall, and has been
applied to a variety of cell types, spanning bacteria, protozoa,
plants, insects and mammals [1–8]. The cell lysate is a crowded
environment of active biomolecules, capable of supporting many
cellular functions. These functions include, but are not limited to,
many metabolic pathways, as well as transcription and transla-
tion. The preparation of lysates for CFPS was signiﬁcantly im-
proved over the years in terms of buffer composition [3],
energy recycling [9], the utilization of various mutated cell
strains [10,11], the supplementation of small molecules [12,13],
the addition of proteins such as T7 RNA polymerase (RNAP) to
generate a transcription/translation coupled system [1,3] and
chaperones to improve the yields of properly folded target
proteins.
In Escherichia coli CFPS, the translation machinery is typically
about 20-fold more dilute than in the cell, decreasing the rates of
initiation, elongation and protein accumulation [14]. As well, the
average distance between two adjacent ribosomes on a single
mRNA strand increases and polysomes are less likely to form
[15]. Despite these differences, CFPS can beneﬁt from the relatively
slower synthesis rate and the greater distance between ribosomesby allowing nascent polypeptide chains more time and space to
form desirable intra-peptide chain contacts, while decreasing the
probability of undesirable, non-speciﬁc inter-peptide chain con-
tacts, thereby increasing the probability of proper folding and
decreasing the probability of aggregation.
This paper will outline progress in the ﬁeld of CFPS that applies
this approach in ways that would be challenging, if not impossible,
to implement using standard in vivo expression systems (Fig. 1).
The use of improved ﬂuorescent proteins, such as Emerald GFP
[16], and of ﬂuorescence detection technologies using a plate read-
er platform, allow real time monitoring of protein expression in a
high-throughput format [17]. These advances allow the straight-
forward screening of the effects on translation rate of various pro-
cedural modiﬁcations. These include the introduction of exogenous
materials, (chemical reagents, proteins, and nucleic acids) and the
substitution of mutated/modiﬁed components of the translation
machinery (ribosomes, mRNAs, tRNAs) for their endogenous
counterparts.
2. Methods of cell-free protein synthesis
The two basic types of CFPS are optimized cell extracts (often
termed lysate-based CFPS), an approach that has been in use for
more than ﬁve decades, and the more recently developed PURE
system, which employs a mixture of a minimal set of puriﬁed com-
ponents (e.g., ribosome, tRNAs, tRNA synthetases, factors, amino
acids, energy sources) required for full-length protein synthesis.
Below we present a brief description of each approach and discuss
various factors that can inﬂuence protein yield and function, before
considering some speciﬁc examples.
Fig. 1. Cell-free protein synthesis and its functionalities. Translation commences upon the addition of DNA (PCR product or plasmid) in a coupled system or by adding
separately transcribed mRNA. Modiﬁed CFPS may exhibit various functionalities, some of which are depicted.
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Some commercially available prokaryotic and eukaryotic CFPS
kits produce transcribed mRNA and translated protein in a coupled
fashion. Adding a DNA encoding the protein of interest along with
T7 or SP6 RNA polymerase (RNAP) generally produces transcribed
mRNA at a faster rate than protein synthesis, with the result that
protein expression is not limited by mRNA availability. There also
exists a protocol for the generation of an E. coli CFPS that utilizes
endogenous RNAP [18]. In general, coupled CFPS expresses pro-
teins in higher yields, and eliminates the separate in vitro tran-
scription step required for mRNA-dependent CFPS (see below).
Coupled CFPS utilizes DNA in three forms: linear PCR product,
linearized plasmid and circular plasmid. Circular DNA plasmid
has typically been preferred to linearized plasmid or PCR products,
due to the greater susceptibility of linear DNAs to nucleolytic
cleavage [19]. On the other hand, use of the linear PCR product
has the distinct advantage of simplicity, since it eliminates the
need for time-consuming cloning steps required when generating
an expression plasmid, that include: ligation of the DNA template
to a linearized plasmid, transformation of the plasmid to compat-
ible cells, selection of colonies harboring the foreign plasmid,
growth of positive colonies in culture for plasmid production, plas-
mid isolation, sequencing, transformation of the plasmid to com-
patible cells, culture growth for protein overexpression,
harvesting and lysis (Fig. 2). In contrast, addition of an ampliﬁed
linear DNA fragment to a CFPS affords single step protein expres-
sion via transcription/translation coupled CFPS, either in analytic
amounts amenable to a high throughput format or in preparative
amounts [20,21]. Utilization of a linear PCR product on an analyt-
ical scale allows facile optimization of translation of the ampliﬁed
DNA fragment, coupled with any desirable extension, as, for exam-
ple, in the case of N-terminal extensions of the adiponectin hyper-
variable domain [21]. Moreover, the yield of expressed protein can
be raised utilizing procedures that increase the stability of the lin-ear PCR-ampliﬁed DNA via both the removal of nucleases [10,20]
and the utilization of overhang extensions to cyclize PCR products,
exploiting the endogenous ligase activity of lysates [22]. In the case
of dengue virus NS2B/NS3 protease, the latter approach gave pro-
tein yields comparable to those obtained using plasmid-based CFPS
[22].
In general, these improvements make PCR product an attractive
alternative to circular plasmid for applications of protein expres-
sion ranging from protein engineering to NMR structural charac-
terization of proteins. Commercial CFPS kits, optimized for
testing the coupled transcription/translation of PCR products, are
available from suppliers such as: 5-prime, Promega, Jena Biosci-
ence, New England Biolabs, Life technologies, Pierce, and Cell-Free
Sciences.
2.2. PURE CFPS
The PUREexpress kit was developed by Ueda and co-workers
[23] and further optimized by New England Biolabs [24,25], which
also distributes it commercially. The PURExpress kit has several
advantages over lysate-based kits. Because it is devoid of any bio-
molecules and metabolites that do not directly participate in pro-
tein synthesis, it lacks both nucleases and proteases that
decrease the lifetime of DNA, mRNA and proteins, and metabolic
enzymes that can convert some nucleotides and amino acids nec-
essary for transcription and translation to non-functional products
not participating in these processes. In addition, it allows straight-
forward elimination of speciﬁc components of the translational
machinery or substitution of exogenous for endogenous compo-
nents. Thus, for example, by omitting the tRNA synthetase PheRS
and all traces of the amino acid Phe, we could make EmGFP synthe-
sis, measured at the single molecule level, totally dependent on the
addition of ﬂuorescently labeled Phe-tRNAPhe as the sole source of
Phe incorporated into protein. An alternative approach, based on
manipulation of a lysate-based kit [17], was successful for parallel
Fig. 2. Protein over-expression using conventional in vivo techniques vs. cell-free protein synthesis. Although both methods end with a cell-lysate that contains the over-
expressed protein, in vivo over-expression requires a multiple-step procedure, whereas CFPS is accomplished in a single step.
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and Phe-tRNAPhe, but was inadequate for single molecule experi-
ments. The main drawback of the PURExpress kit is that the cost
per mg of protein produced is considerably higher than with ly-
sate-based kits.
3. Optimizing CFPS for speciﬁc proteins
3.1. Coupled vs. uncoupled transcription–translation
Prokaryotic and eukaryotic CFPS kits have been described that
lack RNAP activity [5,7,26], such that translation is initiated by
the addition of mRNA, a procedure that can also be used in tran-
scription/translation coupled CFPS. Typical results comparing cou-
pled and uncoupled transcription/translation in E. coli CFPS are
shown in Fig. 3, from which it is clear that much greater quantitiesFig. 3. Plasmid DNA vs. mRNA. A volume of 10 ll CFPS was supplemented with the
indicated amounts of plasmid DNA or mRNA encoding EmGFP. Continuous
ﬂuorescence monitoring was performed in a 384-well plate, set to 30 C using an
excitation and emission wavelength of 486 and 535 nm, respectively.(20–30-fold) of mRNA than plasmid DNA are required for the gen-
eration of similar translation proﬁles (Fig. 3). This is likely due to
the instability of mRNA in the reaction medium, a problem that
is alleviated when mRNA is generated in a continuous fashion.
As a general rule, coupled CFPS is preferred, because it uses
smaller amounts of easy-to-obtain plasmid or PCR-ampliﬁed DNA
and eliminates the time and cost needed for in vitro transcription.
However, there are some instances where the utilization of sepa-
rately prepared mRNA is advantageous. An example is provided
by a study of the effects of post-transcriptional mRNA nucleotide
modiﬁcations on the yields of ﬁreﬂy luciferase and Renilla lucifer-
ase [27]. In this work, synthetic mRNAs were transcribed in vitro
in the presence of known amounts of modiﬁed nucleotides, which
afforded mRNA preparations containing different stoichiometries
of modiﬁed nucleotide. Pseudouridine modiﬁcation was found to
enhance translation in rabbit reticulocyte lysate, (RRL) but not in
wheat germ extract or E. coli CFPS, while s2U and m6A modiﬁca-
tions decreased translation efﬁciency in RRL [27]. Quantiﬁcation
of such effects is an important determinant in tailoring synthetic
mRNAs with desirable properties such as stability, translational
capacity and controlled immunogenicity.
Another example involves the effect of mRNA secondary and
tertiary structures on translation. Such structures may contain
stem-loops, pseudoknots and G-quadruplexes that may fully form
when uncoupled transcription/translation is used, but form only
partially, if at all, when the two processes are coupled. Full forma-
tion allows detailed investigation of how such structures modulate
translation rate, and how modulation can be manipulated, for in-
stance by addition of small molecules and proteins that speciﬁcally
bind and stabilize these structures [28–33].
3.2. 50-UTRs
A 50-UTR upstream from an open reading frame of the expres-
sion plasmid can be important for increasing protein yield. In
bacterial 50-UTRs such optimization can be achieved by placing
the Shine–Dalgarno (SD) sequence at an optimal distance,
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SD sequence interacts with the 30-end of 16S ribosomal RNA
(rRNA) that is part of the small ribosomal (30S) subunit, to allow
efﬁcient initiation. Placement of an A/U-rich enhancer sequence
further upstream allows the SD sequence to interact more effec-
tively with the rRNA [35,36]. An engineered 50-UTR was reported
to induce efﬁcient translation by CFPS kits derived from an array
of cell types, including E. coli, Leishmania tarentolae, insect cells,
wheat germ and rabbit reticulocyte [4]. In eukaryotes, the Inter-
nal Ribosome Entry Site (IRES) is a highly structured element
found within viral mRNA that is able to induce eukaryotic initi-
ation [37,38]. An upstream IRES was shown to be important for
the expression in a HeLa (human)-derived CFPS kit of large pro-
teins such as GCN2 (160 kDa), Dicer (200 kDa) and mTOR
(260 kDa) [8].
3.3. Optimizing temperature and kit composition
Although 37 C is the general default temperature for CFPS,
and typically affords high yields, in some cases a large fraction
of the protein produced is inactive. Lowering the temperature
can increase the active fraction, at the cost of low overall yield.
For example, 30 C is a reasonable compromise in the case of a
GFP [39]. Other proteins may have slightly different optimal tem-
peratures. In addition, there are cases (see below) where it is
desirable to supplement the CFPS kit by addition of, e.g., ions,
small molecules, proteins, and/or nucleic acids [3,12,13,20,40–
43]. Here it is helpful to employ a high throughput assay to mea-
sure the effects of such additions on the synthesis of a test pro-
tein that is easy to monitor. We have recently described such
an assay that monitors the synthesis of fast maturing Emerald
GFP (EmGFP) [17].
3.4. Batch vs. two compartment methods
In CFPS carried out in batch mode, the yield of translated
protein per ml reaction may be limiting due to depletion of
reactants, in particular oxygen in systems using oxidative
phosphorylation for energy generation, and accumulation ofFig. 4. Batch vs. two compartment methods. A batch mode reaction can be performed i
batch reaction mixture on a thin ﬁlm increases the rate of oxygen transfer from the air
compartment approaches allow substrate and byproduct to freely diffuse between two
extract from a substrate feeding solution that is continuously exchanged [45] or overlay t
is also amenable to a high throughput format.inhibitory byproducts. Both of these problems have been suc-
cessfully addressed using the so-called ‘‘thin ﬁlm’’ approach. In
this approach the batch reaction mixture is placed on a thin
ﬁlm [44] (Fig. 4). This provides a large gas/liquid interface
allowing for continuous oxygen transfer from the air, as well
as a large hydrophobic surface. This latter feature facilitates pro-
tein expression and folding by binding inhibitory hydrophobic
molecules such as misfolded polypeptide chains, lipids, and var-
ious small molecules. This approach achieves high concentra-
tions of active protein (as much as 0.5 mg/ml) in a format
that can be scaled up without loss of yield, while allowing
the use of high throughput format for reaction mixture
optimization.
An alternative approach employs two compartments, one con-
taining the modiﬁed extract and one containing a feeding solution
that includes substrates such as amino acids, ATP and GTP, and that
is renewed by continuous ﬂow, permitting substrate replenish-
ment and byproduct removal. In early versions, the two compart-
ments were separated either by a semi-permeable membrane
[45] or by placing the lysate in a dialysis bag immersed in the feed-
ing solution [26,46], while maintaining a continuous ﬂow of the
feeding solution. Although both approaches were capable of main-
taining translation for tens of hours while producing tens of micro-
molar concentration of target proteins, their mechanical
complexity prevented their use in a high throughput format. In a
later methodology that overcomes this limitation, a bilayer is uti-
lized in place of the semipermeable membrane (Fig. 4). Gently
overlaying the feeding solution on top of the modiﬁed extract layer
allows free diffusion of substrates and byproducts between the two
phases [47], without the need for continuous ﬂow. Such an ap-
proach can be performed in well plates using volumes as low as
10 ll [17].
Larger scale reactions utilizing semi-permeable membranes are
possible (e.g., [46] reporting 10 ml scale). Indeed, a recent study re-
ported an industrial scale 100-liter CFPS that showed linear scala-
bility (linear relation between total protein yield and reaction
volume), producing 700 mg protein/L over 10 h, in a controlled
environment bioreactor [48]. Further details about scale and yields
are presented in Carlson et al. [49].n a test-tube or in a well-plate amenable to a high throughput format. Placing the
while the hydrophobic surface facilitates protein expression and folding [44]. Two
phases and either utilize a semipermeable membrane that separates modiﬁed cell
he feeding substrate solution on top of the modiﬁed extract [47]. The latter approach
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4.1. Hard-to-express proteins
Difﬁculties in obtaining a functional protein from a host cell are
quite common and can, in general, be attributed to one or more of
the following problems: cytotoxicity, misfolding and aggregation.
4.1.1. Toxic proteins
Proteins that are toxic to the host cell are often difﬁcult to ex-
press in high yields. CFPS can bypass such problems. Generally, a
protein that is toxic to a particular organism can be expressed in
a lysate from another organism, e.g., expressing E. coli toxin in
wheat germ extract [50–53]. A special case concerns proteins that
inhibit transcription, which can be expressed by adding in vitro
transcribed mRNA to a CFPS kit, effectively uncoupling transcrip-
tion from translation.
4.1.2. Misfolded proteins
During protein over-expression in vivo, a misfolded protein may
either accumulate or be degraded, in either case leading to a poten-
tial burden on the host cell and leaving the experimenter with an
inactive translation product. Some of the possible causes of mis-
folding can be overcome by the use of CFPS. (1) Improper disulﬁde
bonds may be formed during expression in the host cell due to an
unfavorable redox environment. E. coli CFPS supplemented with
various compounds that optimized the redox potential along with
addition of DsbC (prokaryotic disulﬁde bond isomerase) signiﬁ-
cantly improved the yield, of the active forms of several eukaryotic
proteins, including plasminogen activator, an antibody against
hemagglutinin and a urokinase protease [12,13,43]. Commercial
CFPS kits that support correct disulﬁde bond formation are avail-
able from companies such as New England Biolabs and 5-prime.
(2) During the folding pathway, a protein may be trapped in a local
minimum intermediate state. Supplementing the CFPS with chap-
erones may assist with correct folding [20,42]. In one study using
E. coli CFPS to over-express several eukaryotic proteins, the kit
was supplemented with a fusion protein formed between the ribo-
some-binding portion of the E. coli protein trigger factor, which
docked the fusion protein to the exit port of the E. coli ribosome,
and the eukaryotic chaperone BiP. Such supplementation assisted
the nascent eukaryotic polypeptides in acquiring their functional
folds while diminishing aggregation [54].
4.1.3. Aggregated proteins
During protein over-expression, partially folded and/or mis-
folded proteins either still bound to the ribosome or free in the
cytoplasm can undergo aggregation to form so-called ‘inclusion
bodies’, most likely as a result of non-covalent hydrophobic inter-
actions [55]. The ﬂexibility of CFPS allows the facile addition of var-
ious compounds that prevent protein aggregation in CFPS kits
derived from E. coli. The compounds proven useful to alleviate
aggregation in vitro include: polyethylene glycol, polysaccharide
nanogel, ethanol, choline, and amino acids such as Arg, Pro, and
Glu [40,41].
4.2. Ribosome replacement
Removal of endogenous ribosomes from CFPS and their replace-
ment with exogenous ribosomes is easily performed. In lysates, an
ultracentrifugation step is required [17], while in PURExpress a
solution lacking ribosomes is used. Examples of such replacements
include: ﬂuorescently labeled ribosomes for single molecule exper-
iments [17], and ribosomes containing mutations in ribosomal
RNA (rRNA) [56,57] that may affect their activities. CFPS allowsstraightforward study of the properties of variant ribosomes that
may be difﬁcult to determine in live cells, since such variants
may increase the burden on the host cell by inducing delayed
growth rates, stress and even death. Examples of mutated ribo-
somes whose translation activities would be interesting to study
via substitution into CFPS include hyperaccurate [58] and error
prone [59] ribosomes that affect translation ﬁdelity, orthogonal
ribosomes (o-ribosomes) [60] recognizing specialized sets of o-
mRNAs or o-tRNAs, biotinylated ribosomes [61] and ribosomes
containing loop extensions within rRNA [62,63] that are used for
purposes such as ﬂuorescent labeling, surface/bead attachment
or puriﬁcation.
4.3. Preparation of stalled ribosome–nascent chain (RNC) complexes
RNC complexes, which also stably bind mRNA, are desirable for
ribosome display [64], as substrates of chaperones for studies of
co-translational protein folding [65] and for quantiﬁcation of the
fraction of ribosomes active in protein synthesis within a ribosome
preparation [17]. Expressing RNC complexes in cells may induce
stress, as they abrogate protein synthesis. CFPS permits rapid iso-
lation of stalled RNC complexes, while minimizing proteolytic
and nucleolytic cleavages of the bound nascent chain and mRNA,
respectively.
4.4. Amino acid replacement
4.4.1. Obtaining proteins with non-natural amino acids (nnAAs)
The 20 natural amino acids that serve as building blocks of pro-
teins offer a limited repertoire of properties for the design of pro-
teins that can be used for research and engineering purposes. This
limitation can be overcome by the site-speciﬁc incorporation of
nnAAs, which include a much more diverse array of functional side
chains (reviewed by [66]). nnAAs are typically inserted site-specif-
ically by exploitation of the amber stop codon, which is normally
targeted by release factor 1 (RF1) for termination of protein syn-
thesis, using suppressor tRNAs to read-through the amber codon.
Orthogonal aminoacyl-tRNA synthetases (o-aaRSs) are engineered
to aminoacylate suppressor tRNAs with a nnAA [67,68]. The
orthogonality of the suppressor tRNA (o-tRNA) and the o-aaRS is
manifested by a lack of cross-talk with endogenous tRNAs and
aaRSs. In order to obtain in vivo incorporation of a nnAA, the cul-
ture medium is supplemented with the relevant nnAA and the bac-
terial strain is transfected with (i) a single plasmid encoding both
the o-tRNA and the o-aaRS and (ii) another plasmid encoding the
protein of interest that has been mutated to contain an amber stop
codon located at the desired nnAA incorporation site. Upon induc-
tion, the over-expressed protein is either terminated at the amber
stop codon by RF1, or is read-through by the nnAA-o-tRNA. To bias
the competition so as to improve incorporation efﬁciency and full
protein production, RF1 activity can be inhibited, using, for exam-
ple, a targeted antibody [69] or RNA aptamer [70]. Incorporation of
nnAA using CFPS proceeds with higher efﬁciency over the reported
in vivo procedure. One reason is that competition between RF1 and
the aa-o-tRNA in CFPS is much less than in in vivo expression sys-
tems, since the protein synthesis apparatus is much more dilute,
some 20-fold in an optimized CFPS kit derived from E. coli [14].
This reduces the RF1 concentration from 8 lM (in vivo) to
0.4 lM (in CFPS). Another reason may be ascribed to the large vol-
ume utilized for culture growth vs. relatively smaller volumes uti-
lized for CFPS. The high cost of synthetic nnAAs favors the use of
low volume CFPS, as it allows relatively high nnAA concentrations
to be employed, thereby increasing the rate and yield of labeled
protein expression. Such high concentrations are sometimes too
costly to be used when a protein is produced by culture growth.
Fig. 6. Cell-free expression of EmGFP using lysate depleted of Phe, supplemented
with puriﬁed Phe-tRNAPhe. Continuous ﬂuorescence monitoring was performed as
in Fig. 3. EmGFP accumulation was measured as a function of added [Phe-tRNAPhe].
The ﬁgure was obtained from [17].
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ciency is achieved by supplementing the CFPS kit with high con-
centrations of nnAA and o-aaRS [71]. This latter study illustrates
the advantages of the CFPS approach for nnAA incorporation,
which yielded, per ml culture, 0.9–1.7 mg protein harboring a sin-
gle p-azido-L-phenylalanine or p-propargyloxy-L-phenylalanine,
with an incorporation efﬁciency of 50–88%, depending on the posi-
tion of incorporation [71]. By comparison, in vivo expression of
EGFP using a specialized RF1-knockout E. coli strain JX33 [72] that
eliminates the competition between RF-1 and the amber tRNA
repressor, produced, per ml culture, 3.5 lg protein containing
one or two p-acetyl-L-phenylalanine (pActF) and 5.4 lg protein
containing three pActFs, corresponding to a nnAA incorporation
efﬁciency in the range 23–36%. Given the generally high costs of
synthetic nnAAs, the much higher yield of nnAA-containing protein
per ml of solution is an important advantage of the CFPS over the
in vivo approach.
4.4.2. Obtaining proteins with isotope-labeled amino acids
Isotope-labeled amino acids allow detection of radioactive pro-
teins containing unstable isotopes, and FT-IR and NMR character-
ization of proteins containing stable isotopes. For purposes of
site-speciﬁc labeling, auxotrophic cells are grown in the presence
of isotopically labeled amino acid. However, due to in vivo meta-
bolic activity, some fraction of the labeled amino acids is converted
to other amino acids, leading to scrambling. CFPS minimizes
scrambling, since some metabolic pathways are compromised dur-
ing cell extract preparation and speciﬁc metabolic inhibitors can be
added to the CFPS kit [73]. Examples of expression of isotope-la-
beled proteins in CFPS are reviewed by [74,75].
A novel procedure was recently reported [17], making protein
expression completely dependent on the addition of a speciﬁc
exogenous amino acid, Phe in the example described. In this proce-
dure all endogenous amino acids are removed from a lysate by
dialysis in the presence of two inhibitors: (1) a general protease
inhibitor cocktail that suppresses proteolytic cleavages that pro-
duce free amino acids and (2) a speciﬁc PheRS inhibitor that sup-
presses aminoacylation of tRNAPhe by free Phe. Such depleted
lysates are then reconstituted with an amino acids mixture lacking
Phe, such that the CFPS solution is incapable of expressing the test
protein, EmGFP. Addition of increasing concentrations of Phe, re-
sulted in EmGFP expression, with a maximum level seen at
80 lM of added Phe (Fig. 5). The total dependence of EmGFP
expression on added Phe means that this procedure could be used
to produce proteins that are homogeneously labeled with an isoto-
pically labeled form of Phe.Fig. 5. Cell-free expression of EmGFP using lysate depleted of Phe, supplemented
with the amino acid Phe. Continuous ﬂuorescence monitoring was performed as in
Fig. 3. EmGFP accumulation was measured as a function of added [Phe]. The ﬁgure
was obtained from [17].4.5. tRNA replacement
Substitution of endogenous aminoacyl-tRNA (aa-tRNA) by an
exogenously added counterpart can be important for protein syn-
thesis studies focused on modiﬁed (e.g., isotope-labeled or non-
natural) amino acid incorporation and/or modiﬁed tRNA (e.g., mu-
tated, chemically/enzymatically modiﬁed, ﬂuorescently labeled)
interaction with the ribosome.
Replacing the majority of the endogenous tRNA pool in a CFPS
kit with exogenous tRNA was previously reported [76,77]. A spe-
ciﬁc isoacceptor tRNA can also be selectively removed from bulk
tRNA and replaced with a corresponding modiﬁed aa-tRNA [78].
Alternatively, a CFPS kit can be selectively depleted for a speciﬁc
amino acid (Section 4.3.2) such that reconstitution of the transla-
tion activity is totally dependent on the addition of the amino acid
in the form of aa-tRNAaa. Fig. 6 is an example of such an approach.
Here, EmGFP expression reached a maximum at 8 lM of added
Phe-tRNAPhe. This approach, was applied to test the activities of
ﬂuorescent-labeled tRNAs [17] that are used in single-molecule
experiments examining regulatory mechanisms of protein synthe-
sis [31]. It could also be used for testing the activities of other mod-
iﬁed aa-tRNAaas, such as those charged with non-natural amino
acids, or lacking speciﬁc posttranscriptional modiﬁcations [79].
5. Conclusions and outlook
The ﬁrst CFPS systemwas reported in the 1950s by [80] and was
later employed in the seminal work of Nirenberg and Matthaei, in
the 1960s [2], as the tool that allowed deciphering of the genetic
code. Since then, many improvements in CFPS have been reported,
directed toward both increasing expression yields and incorporat-
ing new functions and capabilities. The open nature of CFPS allows
both changes of the concentrations of various components of the
translation machinery so as to optimize functional protein synthe-
sis and replacement of endogenous components with exogenous
components (e.g., isotope-labeled and non-natural amino acids,
ﬂuorescent labeled tRNAs, mutant ribosomes) that permit many
useful applications. At present, such manipulations are typically
performed one at a time, but it is to be expected that future studies
will increasingly involve combinations, e.g., supplementing an
E. coli system that efﬁciently incorporates nnAAs with disulﬁde
bond isomerases, and chaperones to insure that the modiﬁed pro-
tein is properly folded.
A particularly attractive goal for future work would be to devel-
op a bacterial-eukaryotic CFPS hybrid to allow eukaryotic protein
G. Rosenblum, B.S. Cooperman / FEBS Letters 588 (2014) 261–268 267expression to be carried out by the more efﬁcient bacterial transla-
tion machinery by substitution/supplementation of the bacterial
machinery with eukaryotic tRNAs, aaRSs, chaperones and post-
translation modiﬁcation enzymes and by provision of an appropri-
ate redox environment. Ultimately, one can envision that commer-
cial ﬁrms will offer CFPS kits tailored to meet the needs of
individual scientists that will replace current protocols for protein
expression that can be quite laborious. In this idealized scenario, a
scientist will add a DNA coding region, ampliﬁed by PCR or ligated
in a plasmid, to a customized CFPS, that will produce any protein in
large quantities with high functional activity, and with amino acids
that are either naturally occurring, isotopically labeled or non-
natural.
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